bisoprolol has been researched along with Cardiac Arrest, Sudden in 14 studies
Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.
Excerpt | Relevance | Reference |
---|---|---|
"Whether all patients with congestive heart failure (CHF) need to reach the target dose of beta-blocker to obtain a benefit in terms of survival remains uncertain." | 6.71 | Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study(CIBIS II). ( Funck-Brentano, C; Jaillon, P; Lechat, P; Mary-Krause, M; Simon, T, 2003) |
"Baroreflex sensitivity was assessed in 287 patients with history of myocardial infarction and left ventricular ejection fraction < or =40% by phenylephrine test and was found to be depressed (4." | 3.72 | [Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction]. ( Bozhko, AA; Kanopskiĭ, SG; Staritskiĭ, AG, 2004) |
"The occurrence of sudden cardiac death (SCD) in patients with silent ischemia after myocardial infarction (MI) and the factors facilitating SCD are unknown." | 2.74 | Sudden cardiac death in patients with silent myocardial ischemia after myocardial infarction (from the Swiss Interventional Study on Silent Ischemia Type II [SWISSI II]). ( Abbate, A; Erne, P; Jamshidi, P; Kobza, R; Pfisterer, M; Schoenenberger, AW; Stuck, AE; Zuber, M, 2009) |
"Whether all patients with congestive heart failure (CHF) need to reach the target dose of beta-blocker to obtain a benefit in terms of survival remains uncertain." | 2.71 | Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study(CIBIS II). ( Funck-Brentano, C; Jaillon, P; Lechat, P; Mary-Krause, M; Simon, T, 2003) |
"The heart failure is one of the pathologies with major social and economic impact in the western world." | 2.44 | [Chronic heart failure and sudden death: the message of CIBIS-III]. ( Dequarti, MC; Poggio, L; Vanoli, E, 2007) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (21.43) | 18.2507 |
2000's | 8 (57.14) | 29.6817 |
2010's | 1 (7.14) | 24.3611 |
2020's | 2 (14.29) | 2.80 |
Authors | Studies |
---|---|
Sánez Tähtisalo, H | 1 |
Hiltunen, TP | 1 |
Kenttä, T | 1 |
Junttila, J | 1 |
Oikarinen, L | 1 |
Virolainen, J | 1 |
Kontula, KK | 1 |
Porthan, K | 1 |
Sirico, G | 1 |
Montisci, A | 1 |
Secchi, F | 1 |
Mantica, M | 1 |
Schoenenberger, AW | 2 |
Kobza, R | 1 |
Jamshidi, P | 1 |
Zuber, M | 2 |
Abbate, A | 1 |
Stuck, AE | 1 |
Pfisterer, M | 2 |
Erne, P | 2 |
Krum, H | 1 |
van Veldhuisen, DJ | 1 |
Funck-Brentano, C | 2 |
Vanoli, E | 2 |
Silke, B | 1 |
Erdmann, E | 1 |
Follath, F | 1 |
Ponikowski, P | 1 |
Goulder, M | 1 |
Meyer, W | 1 |
Lechat, P | 2 |
Willenheimer, R | 1 |
Simon, T | 1 |
Mary-Krause, M | 1 |
Jaillon, P | 1 |
Kanopskiĭ, SG | 1 |
Staritskiĭ, AG | 1 |
Bozhko, AA | 1 |
Kowey, PR | 1 |
Burckhardt, D | 1 |
Kiowski, W | 1 |
Dubach, P | 1 |
Resink, T | 1 |
Dequarti, MC | 1 |
Poggio, L | 1 |
Drummond, GA | 1 |
Squire, IB | 1 |
Kendall, MJ | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Long Term Study on the Possible Beneficial Effects of Catheterised Renal Denervation in Patients With Heart Failure and Left Ventricular Systolic Dysfunction Who Are Already on Standard Medical Therapy.[NCT01870310] | 50 participants (Anticipated) | Interventional | 2012-06-30 | Recruiting | |||
Bisoprolol Plasma Residual Concentrations for the Optimization of Drug Management in Heart Failure With Mild to Reduced Ejection Fraction[NCT03644446] | 81 participants (Anticipated) | Observational [Patient Registry] | 2017-11-02 | Recruiting | |||
A Multicenter,Randomized, Double Blind, Double Dummy, Parallel Group Study to Compare Effects of Coreg CR and Coreg IR on Left Ventricular End Systolic Volume Index in Subjects With Stable Chronic Heart Failure[NCT00323037] | Phase 3 | 318 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
Collaborative Systematic Overview of Randomised Controlled Trials of Beta-Blockers in the Treatment of Heart Failure[NCT00832442] | 18,240 participants (Anticipated) | Observational | 2008-08-31 | Enrolling by invitation | |||
The PACE-MI Registry Study - Outcomes of Beta-blocker Therapy After Myocardial Infarction (OBTAIN)[NCT00430612] | 7,057 participants (Actual) | Observational [Patient Registry] | 2009-05-31 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
Intervention | percentage of change (Mean) |
---|---|
Carvedilol Immediate Release | -0.88 |
Carvedilol Controlled Release | -0.86 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
Intervention | percentage of change (Mean) |
---|---|
Carvedilol Immediate Release | 24.00 |
Carvedilol Controlled Release | 53.37 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
Intervention | percentage of change (Mean) |
---|---|
Carvedilol Immediate Release | -0.20 |
Carvedilol Controlled Release | -0.45 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
Intervention | percentage of change (Mean) |
---|---|
Carvedilol Immediate Release | -0.33 |
Carvedilol Controlled Release | -0.36 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
Intervention | percentage of change (Mean) |
---|---|
Carvedilol Immediate Release | -0.76 |
Carvedilol Controlled Release | -0.83 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
Intervention | percentage of change (Mean) |
---|---|
Carvedilol Immediate Release | .08 |
Carvedilol Controlled Release | .05 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
Intervention | percentage of change (Mean) |
---|---|
Carvedilol Immediate Release | .08 |
Carvedilol Controlled Release | .08 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
Intervention | percentage of change (Mean) |
---|---|
Carvedilol Immediate Release | -36.61 |
Carvedilol Controlled Release | -42.22 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
Intervention | percentage of change (Mean) |
---|---|
Carvedilol Immediate Release | -18.29 |
Carvedilol Controlled Release | -20.57 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
Intervention | percentage of change (Mean) |
---|---|
Carvedilol Immediate Release | -36.61 |
Carvedilol Controlled Release | -43.00 |
Maintenance Visit 3 minus Baseline. Maintenance Visit 3 occurred 24 weeks after entry into the maintenance period. The maintenance period started after completion of a titration period of variable duration. (NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
Intervention | mL/m^2 (Mean) |
---|---|
Coreg Immediate Release | -18.36 |
Coreg Controlled Release | -20.81 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
Intervention | percentage of change (Mean) |
---|---|
Carvedilol Immediate Release | 9.5 |
Carvedilol Controlled Release | -9.29 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
Intervention | percentage of change (Mean) |
---|---|
Carvedilol Immediate Release | .07 |
Carvedilol Controlled Release | .05 |
SAEs experienced (NCT00323037)
Timeframe: 24 weeks after entry into the maintenance phase (after unblinding)
Intervention | number of SAEs (Number) |
---|---|
Carvedilol Immediate Release | 40 |
Carvedilol Controlled Release | 35 |
(NCT00323037)
Timeframe: Up to 32 weeks (titration and maintenance phases)
Intervention | subjects in each treatment group (Number) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Study Entry (10mg Coreg CR, 3.125mg Coreg IR) | Maintenance Entry (10mg Coreg CR, 3.125mg Coreg IR) | End of Study (10mg Coreg CR, 3.125mg Coreg IR) | Study Entry (20mg Coreg CR, 6.25mg Coreg IR) | Maintenance Entry (20mg Coreg CR, 6.25mg Coreg IR) | End of Study (20mg Coreg CR, 6.25mg Coreg IR) | Study Entry (40mg Coreg CR, 12.5mg Coreg IR) | Maintenance Entry (40mg Coreg CR, 12.5mg Coreg IR) | End of Study (40mg Coreg CR, 12.5mg Coreg IR) | Study Entry (80mg Coreg CR, 25mg Coreg IR) | Maintenance Entry (80mg Coreg CR, 25mg Coreg IR) | End of Study (80mg Coreg CR, 25mg Coreg IR) | |
Carvedilol Controlled Release | 83 | 0 | 4 | 39 | 9 | 16 | 27 | 16 | 22 | 4 | 114 | 111 |
Carvedilol Immediate Release | 79 | 0 | 7 | 61 | 13 | 16 | 21 | 12 | 21 | 4 | 116 | 121 |
(NCT00323037)
Timeframe: Up to 32 weeks (titration and maintenance phases)
Intervention | participants in each treatment group (Number) | ||
---|---|---|---|
Hospitalization for Heart Failure | Hospitalization Due to Any Cause | Hospitalization or Death | |
Carvedilol Controlled Release | 6 | 29 | 29 |
Carvedilol Immediate Release | 6 | 31 | 32 |
2 reviews available for bisoprolol and Cardiac Arrest, Sudden
Article | Year |
---|---|
A review of carvedilol arrhythmia data in clinical trials.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Ca | 2005 |
[Chronic heart failure and sudden death: the message of CIBIS-III].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 2007 |
5 trials available for bisoprolol and Cardiac Arrest, Sudden
Article | Year |
---|---|
Sudden cardiac death in patients with silent myocardial ischemia after myocardial infarction (from the Swiss Interventional Study on Silent Ischemia Type II [SWISSI II]).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angioplasty, Balloon, Coronary; Antihypertensi | 2009 |
Effect on mode of death of heart failure treatment started with bisoprolol followed by Enalapril, compared to the opposite order: results of the randomized CIBIS III trial.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Chronic Dis | 2011 |
Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study(CIBIS II).
Topics: Adrenergic beta-Antagonists; Bisoprolol; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; D | 2003 |
Effects of anti-ischaemic drug therapy in silent myocardial ischaemia type I: the Swiss Interventional Study on Silent Ischaemia type I (SWISSI I): a randomized, controlled pilot study.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Bisoprolol; Death, Su | 2007 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou | 1999 |
7 other studies available for bisoprolol and Cardiac Arrest, Sudden
Article | Year |
---|---|
Effect of four classes of antihypertensive drugs on cardiac repolarization heterogeneity: A double-blind rotational study.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antihypertensive Agents; Bisoprolol; | 2020 |
Myotonic dystrophy type 1 and high ventricular vulnerability at the electrophysiological evaluation: ICD yes or not?
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Bisoprolol; Clinical Decision-Making; Death, Sudden, | 2020 |
[Longevity promoting beta blocker. Soon in 1st place in heart failure?].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Cause of Death; C | 2003 |
[Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti | 2004 |
[Beginning therapy of heart failure with beta blockers. Do these patients survive longer?].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Death, Sudden, Ca | 2005 |
The Cardiac Insufficiency Bisoprolol Study II.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Death, Sudden, Cardiac; Heart Failure; Humans | 1999 |
Possible mechanisms of action in the positive effect of beta blockers in heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Death, Sudden, Cardiac; Heart Failure; Humans; Myocardial I | 1999 |